Group 1 - The core viewpoint of the article highlights that Sanbo Brain Science's stock closed at 66.46 yuan, down 2.01%, with a rolling PE ratio of 124.57 times and a total market value of 13.69 billion yuan [1] - The average PE ratio for the medical services industry is 49.76 times, with a median of 64.18 times, placing Sanbo Brain Science at the 39th position in the industry ranking [1] - As of March 31, 2025, the number of shareholders for Sanbo Brain Science increased to 37,673, with an average holding value of 352,800 yuan and an average holding quantity of 27,600 shares [1] Group 2 - Sanbo Brain Science Hospital Management Group Co., Ltd. primarily engages in clinical medical services, with main products including medical services, pharmaceuticals, supply chain, and other businesses [1] - In the latest quarterly report for Q1 2025, the company achieved an operating income of 393 million yuan, a year-on-year increase of 16.78%, and a net profit of 38.31 million yuan, up 14.56%, with a gross profit margin of 26.44% [1]

Group 1 - The core viewpoint of the articles highlights the performance and valuation of Zhendermedical, which closed at 23.68 yuan with a PE ratio of 17.38, marking a new low in 165 days, and a total market capitalization of 6.31 billion yuan [1][2] - The average PE ratio for the medical device industry is 56.58, with a median of 39.97, positioning Zhendermedical at 37th place within the industry [1][2] - As of March 31, 2025, Zhendermedical has 24,690 shareholders, an increase of 1,808 from the previous count, with an average holding value of 352,800 yuan and an average shareholding of 27,600 shares [1] Group 2 - Zhendermedical specializes in the research, production, and sales of medical and health products, with key offerings in basic care, surgical infection control, pressure treatment, stoma care, and modern wound care [1] - The latest quarterly report for Q1 2025 shows Zhendermedical achieved a revenue of 999.2 million yuan, a year-on-year increase of 2.87%, while net profit was 51.24 million yuan, reflecting a year-on-year decrease of 30.19%, with a gross margin of 34.28% [1]

Group 1 - The core viewpoint of the articles highlights the performance and valuation of Liaoport Co., Ltd., indicating a recent increase in stock price and a low rolling PE ratio compared to industry averages [1][2] - As of August 15, Liaoport's stock closed at 1.61 yuan, up 1.26%, with a rolling PE ratio of 23.38, marking a 143-day low and a total market capitalization of 38.488 billion yuan [1] - The average PE ratio for the shipping and port industry is 14.71, with a median of 15.97, positioning Liaoport at the 26th rank within the industry [1][2] Group 2 - As of March 31, 2014, Liaoport had 89,923 shareholders, a decrease of 3,348 from the previous count, with an average holding value of 352,800 yuan and an average shareholding of 27,600 shares [1] - The main business activities of Liaoport include oil/liquid chemical product terminals, container terminals, automobile terminals, bulk cargo terminals, grain terminals, passenger roll-on/roll-off terminals, and port value-added services [1] - The latest financial report for Q1 2025 shows Liaoport achieved an operating income of 2.527 billion yuan, a year-on-year decrease of 12.51%, and a net profit of 204 million yuan, down 45.09%, with a gross profit margin of 22.86% [1]

8月15日，东南电子今日收盘22.31元，上涨1.32%，滚动市盈率PE（当前股价与前四季度每股收益总和 的比值）达到57.31倍，总市值26.81亿元。 从行业市盈率排名来看，公司所处的电子元件行业市盈率平均75.28倍，行业中值62.88倍，东南电子排 名第80位。 股东方面，截至2025年3月31日，东南电子股东户数7069户，较上次减少1434户，户均持股市值35.28万 元，户均持股数量2.76万股。 东南电子股份有限公司的主营业务是微动开关产品的设计、研发、生产及销售。公司的主要产品是家电 微动开关及组件、汽车微动开关及组件、电动工具微动开关、智能低压微动开关。公司及公司产品获得 了多项荣誉，2017年，公司被浙江省经济和信息化委员会评为"浙江省工业设计中心"；2018年，公司被 浙江省科学技术厅评为"省级高新技术企业研究开发中心"；2019年，公司被浙江省经济和信息化委员会 评为"浙江省重点高新技术产品"；2021年，被浙江省经济和信息化厅评为"浙江省隐形冠军企业"、被浙 江省经济和信息化厅评为"浙江省'专精特新'中小企业"、被工业和信息化部办公厅评为"专精特新'小巨 人'企业"等。2023年， ...

Group 1 - The core viewpoint of the articles highlights that Dabo Medical's stock closed at 59.21 yuan, with a 3.35% increase, and a rolling PE ratio of 61.56 times, leading to a total market capitalization of 24.514 billion yuan [1] - The average PE ratio for the medical device industry is 56.58 times, with a median of 39.97 times, positioning Dabo Medical at the 90th rank within the industry [1] - Dabo Medical's main business involves the production, research, and sales of high-value medical consumables, including a wide range of orthopedic and surgical products [1] Group 2 - The latest quarterly report for Q1 2025 shows that Dabo Medical achieved an operating revenue of 550 million yuan, representing a year-on-year increase of 28.80%, and a net profit of 103 million yuan, with a year-on-year growth of 67.04% [1] - The sales gross margin for Dabo Medical stands at 69.64% [1] - The company experienced a net outflow of 7.0504 million yuan in principal funds on August 15, with a total outflow of 131.9464 million yuan over the past five days [1]

Core Viewpoint - Yueyang Xingchang's stock closed at 16.39 yuan on August 15, with a PE ratio of 109.90, marking a new low in 16 days, and a total market capitalization of 6.059 billion yuan [1] Company Summary - Yueyang Xingchang specializes in the development, production, and sales of petrochemical products, including chemical new materials, energy conservation and environmental protection, and retail of refined oil [1] - The company's main products include methyl tert-butyl ether, liquefied petroleum gas, propylene, industrial isooctane, ortho-cresol, calcined petroleum coke, and special polypropylene [1] - For Q1 2025, the company reported operating revenue of 1.063 billion yuan, a year-on-year increase of 27.85%, and a net profit of 13.6081 million yuan, a year-on-year decrease of 37.00%, with a gross profit margin of 18.85% [1] Industry Summary - The average PE ratio for the petroleum industry is 12.81, with a median of 28.49, placing Yueyang Xingchang at the 18th position in the industry ranking [2] - The company experienced a net inflow of 5.1876 million yuan in main funds on August 15, but had a total outflow of 25.0874 million yuan over the past five days [1]

8月15日，海德股份今日收盘6.65元，上涨1.22%，滚动市盈率PE（当前股价与前四季度每股收益总和的 比值）达到67.04倍，总市值129.98亿元。 从行业市盈率排名来看，公司所处的多元金融行业市盈率平均50.44倍，行业中值30.65倍，海德股份排 名第16位。 资金流向方面，8月15日，海德股份主力资金净流出26.63万元，近5日总体呈流出状态，5日共流出 2268.58万元。 海南海德资本管理股份有限公司的主营业务是科技清收个贷不良服务业务、机构困境资管业务、优质资 产管理业务。公司的主要产品是资产管理、金融科技服务。 最新一期业绩显示，2025年一季报，公司实现营业收入2.21亿元，同比-36.02%；净利润9704.45万元， 同比-58.40%，销售毛利率98.91%。 序号股票简称PE(TTM)PE(静)市净率总市值(元)12海德股份67.0439.372.44129.98亿行业平均 50.4442.691.86234.24亿行业中值30.6526.271.83191.77亿1江苏金租11.2711.501.36338.27亿2陕国投 A13.6914.091.05191.77亿3越秀资本 ...

Group 1 - The core viewpoint of the articles highlights the financial performance and market position of Jiuzhou Yiguai Environmental Technology Co., Ltd, which has a high PE ratio compared to its industry peers [1][2] - Jiuzhou Yiguai's current stock price is 13.13 yuan, with a PE ratio of 167.07, significantly higher than the industry average of 58.87 and the median of 33.55 [1][2] - The company's total market capitalization is 1.973 billion yuan, ranking 107th in the environmental industry based on PE ratio [1][2] Group 2 - As of the first quarter of 2025, only two institutions hold shares in Jiuzhou Yiguai, with a total of 144,000 shares valued at 0.02 million yuan [1] - The company reported a revenue of 26.0584 million yuan for the first quarter of 2025, reflecting a year-on-year decrease of 44.47%, and a net loss of approximately 6.0249 million yuan, with a gross profit margin of 15.59% [1] - Jiuzhou Yiguai specializes in research and development, manufacturing, engineering design, marketing, testing consulting, and operational management services related to rail transit vibration and noise reduction technology [1]

截至2025年一季报，共有3家机构持仓振德医疗，其中基金3家，合计持股数145.13万股，持股市值0.31 亿元。 8月14日，振德医疗今日收盘23.22元，下跌1.32%，滚动市盈率PE（当前股价与前四季度每股收益总和 的比值）达到17.04倍，总市值61.87亿元。 从行业市盈率排名来看，公司所处的医疗器械行业市盈率平均55.76倍，行业中值39.14倍，振德医疗排 名第36位。 序号股票简称PE(TTM)PE(静)市净率总市值(元)5振德医疗17.0416.061.0861.87亿行业平均 55.7651.784.91117.92亿行业中值39.1439.592.8556.79亿1九安医疗11.1811.310.88188.72亿2英科医疗 14.7815.931.32233.49亿3山东药玻16.1716.211.86152.90亿4新华医疗16.3115.111.33104.53亿6奥美医疗 17.0716.731.7561.68亿7九强生物17.6516.412.1687.42亿8康德莱18.2218.241.5139.27亿9奥泰生物 18.4419.441.4958.81亿10维力医疗18.4 ...

8月14日，中国瑞林今日收盘51.77元，下跌1.93%，滚动市盈率PE（当前股价与前四季度每股收益总和 的比值）达到39.48倍，总市值62.12亿元。 截至2025年一季报，共有7家机构持仓中国瑞林，其中基金7家，合计持股数0.04万股，持股市值0.00亿 元。 中国瑞林工程技术股份有限公司的主营业务是为境内外有色金属采矿、选矿、冶炼及加工领域客户提供 涵盖设计咨询、总承包、装备集成、数智转型等全链条技术解决方案及全过程服务；同时积极拓展生态 环境治理、市政基础设施等领域的创新解决方案。公司的主要产品是工程设计、工程咨询、其他工程服 务、工程总承包业务、专用设备研发制造、系统集成。公司（含南昌有色冶金设计研究院时期）累计获 得国家级、省部级、市级等荣誉1,210项，累计获得国家级、省部级、市级等荣誉1210项，其中科技类 奖项216项，专利奖7项，工程类设计、咨询奖等其他荣誉987项。其中，国家科学技术进步一等奖1项、 二等奖8项、三等奖2项。 最新一期业绩显示，2025年一季报，公司实现营业收入3.44亿元，同比-8.83%；净利润1385.79万元，同 比62.77%，销售毛利率17.63%。 序号股 ...